Top-Rated StocksTop-RatedNASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $25.33 -0.55 (-2.13%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$25.33▼$26.9850-Day Range$19.78▼$25.8852-Week Range$14.89▼$32.53Volume821,114 shsAverage Volume752,987 shsMarket Capitalization$2.30 billionP/E RatioN/ADividend YieldN/APrice Target$51.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Rocket Pharmaceuticals alerts: Email Address Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside102.3% Upside$51.25 Price TargetShort InterestBearish10.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.31Based on 11 Articles This WeekInsider TradingSelling Shares$358,654 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.96) to ($2.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.03 out of 5 starsMedical Sector203rd out of 936 stocksPharmaceutical Preparations Industry85th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Rocket Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.62% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 14.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.8 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Rocket Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $358,654.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.96) to ($2.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -8.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesJuly 25 at 6:48 AM | insidertrades.comInsider Selling: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells 812 Shares of StockJuly 10, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Sells $61,700.14 in StockJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 9:24 PM | yahoo.comBuild Your Own LEGO Rocket Ship and Set It Into Orbit as Part of LEGO’s SDCC Booth ExperienceJuly 26 at 4:23 PM | apnews.comRocket fired into Israel from northern GazaJuly 23, 2024 | benzinga.comCybertruck Hits Fortnite, Rocket League: Elon Musk's Vehicle Now Featured In Games Backed By Disney Rival Bob IgerJuly 23, 2024 | yahoo.comThe Cybertruck is coming to Fortnite and Rocket League because we're being punishedJuly 22, 2024 | msn.comRocket Row ribbon cutting marks return of Alabama rocket center's 'spaceline'July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | msn.comTesla's Cybertruck Is Driving Into Fortnite and Rocket League This WeekJuly 21, 2024 | msn.comNew Guardians of the Galaxy: Cosmic Rewind Apparel Featuring Groot, Rocket, and Spaceship EarthJuly 19, 2024 | barrons.comTop Official In China's Rocket Force Investigated For Corruption: State MediaJune 28, 2024 | investopedia.comFDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy TreatmentJune 28, 2024 | seekingalpha.comRocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick FixMay 29, 2024 | markets.businessinsider.comRocket Pharma Says EC Granted Orphan Medicinal Product Designation For RP-A601May 29, 2024 | businesswire.comRocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic CardiomyopathyMay 27, 2024 | msn.comDyson exec, Rocket Lab man back Hamilton electric motorbike maker FTN MotionMay 27, 2024 | msn.comRocket Lab's Precision Launch Elevates NASA's Climate Study MissionSee More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees268Year Founded2018Price Target and Rating Average Stock Price Target$51.25 High Stock Price Target$65.00 Low Stock Price Target$39.00 Potential Upside/Downside+102.3%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.10% Return on Assets-46.90% Debt Debt-to-Equity Ratio0.04 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book4.64Miscellaneous Outstanding Shares90,780,000Free Float62,549,000Market Cap$2.30 billion OptionableOptionable Beta1.13 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Kinnari Patel M.B.A. (Age 44)Pharm.D., Head of R&D, President & COO Comp: $849.93kMr. Mayo Pujols (Age 54)Chief Technical Officer Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Chief Business Officer Comp: $619.13kMr. Aaron Ondrey (Age 47)Chief Financial Officer Mr. Martin Louis Wilson J.D. (Age 48)General Counsel, Chief Compliance Officer & Chief Corporate Officer Comp: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Chief People OfficerMr. Jonathan Schwartz M.D. (Age 59)Chief Medical & Gene Therapy Officer Comp: $557.79kDr. Gayatri R. Rao J.D.M.D., Senior VP of Clinical Safety & Chief Regulatory OfficerMr. Carlos MartinChief Commercial Operations & Revenue OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSDicerna PharmaceuticalsNASDAQ:DRNAAurinia PharmaceuticalsNASDAQ:AUPHY-mAbs TherapeuticsNASDAQ:YMABHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 22,521 shares on 7/26/2024Ownership: 0.264%EFG Asset Management North America Corp.Bought 71,044 shares on 7/26/2024Ownership: 0.245%John MilitelloSold 812 sharesTotal: $18,692.24 ($23.02/share)Hennion & Walsh Asset Management Inc.Sold 27,177 shares on 7/20/2024Ownership: 0.225%Nisa Investment Advisors LLCBought 764 shares on 7/20/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $29.97 at the start of the year. Since then, RCKT stock has decreased by 15.5% and is now trading at $25.33. View the best growth stocks for 2024 here. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) posted its quarterly earnings data on Monday, May, 6th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping analysts' consensus estimates of ($0.67) by $0.01. Who are Rocket Pharmaceuticals' major shareholders? Top institutional shareholders of Rocket Pharmaceuticals include Bank of New York Mellon Corp (0.26%), EFG Asset Management North America Corp. (0.24%), Hennion & Walsh Asset Management Inc. (0.22%) and Harbor Capital Advisors Inc. (0.11%). Insiders that own company stock include Rtw Investments, Lp, Gaurav Shah, Gotham Makker, Kinnari Patel, David P Southwell, Jonathan David Schwartz, Mark Andrew White, Martin Wilson and John Militello. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET) and Micron Technology (MU). This page (NASDAQ:RCKT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
